Lululemon's turnaround story is in serious trouble before the new CEO even starts

Lululemon reported a steep drop in comparable sales and slashed its full-year revenue forecast by roughly $650 million, a cut so large it signals the brand's struggles go deeper than a single bad quarter.

With incoming CEO Heidi O'Neill taking over next week, the company is handing her a burning building, not a fixer-upper, and the fashion missteps analysts are flagging will not be solved by a leadership change alone.

The market punished Ionis for a historic FDA approval it had already priced in

Ionis Pharmaceuticals won approval for the first-ever treatment for a rare genetic disorder that destroys the brain's white matter, a genuine scientific milestone that would normally send biotech shares soaring.

The stock's drop on approval day suggests investors had already priced in the win and are now rotating out, a reminder that good news in biotech is often a sell-the-news moment rather than a reward.

Thomson Reuters' data breach deserves more alarm than the market's shrug suggests

Thomson Reuters disclosed that an unauthorized party accessed court record files across 11 U.S. states, a Canadian province, and a U.S. territory, making it a breach that touched government infrastructure, not just corporate data.

The fact that shares rose on breach day says less about the incident's severity and more about how numb markets have become to cybersecurity failures at large companies.